Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Early-stage Breast Cancer, Gynecologic Cancer, Peripheral Neuropathy
Conditions
Keywords
Chemotherapy Induced Peripheral Neuropathy, Hydroxycloroquine, Diffusion Tensor Imaging, Breast Cancer, Gynecologic Cancer, Paclitaxel, Neoadjuvant chemotherapy
Brief summary
The study is being done to research if hydroxychloroquine can prevent chemotherapy induced peripheral neuropathy. Certain chemotherapy drugs, like paclitaxel, are known to cause neuropathy which can impact quality of life. Currently, there are no options for preventing peripheral neuropathy. In addition, there are no useful methods to assess peripheral nerve damage. This study will also explore using a study MRI of patients' feet prior to starting chemotherapy and after they have completed chemotherapy to see if there is any difference in their nerve structure.
Interventions
DRUGHydroxychloroquine
Hydroxychloroquine will be administered at 600 mg po BID for 3 days prior to starting chemotherapy, continued during the course of chemotherapy, and for 7 days after chemotherapy.
Sponsors
University of Arizona
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with stage 1-3 breast cancer or gynecological cancer treated with curative intent * Age ≥ 21 years old * No prior neurotoxic chemotherapies * No other neurotoxic chemotherapies planned during paclitaxel treatment (i.e, platinum) * Need to be treated with paclitaxel weekly x 12 doses as determined by their treating physician * Be able to undergo MR Imaging * Be willing to comply with scheduled visits, treatment plan, and MR imaging * Adequate organ function as defined as: Hematologic: Absolute neutrophil count (ANC) ≥ 1500/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL Hepatic: Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN Renal: Estimated creatinine clearance (CrCl)≥ 50 mL/min by Cockcroft-Gault formula
Exclusion criteria
* Stage IV cancer * CTCAE neurological function \> grade 1 at baseline * Mental limitation that precludes understanding of or completion of questionnaires * History of diabetes or other neurological disorders * Preexisting peripheral neuropathy * Prior exposure to neurotoxic chemotherapy * Currently taking medication to treat or prevent neuropathy * Have non-MRI compatible metallic objects on/in body * Have metallic hardware in the lower extremity which is MR compatible however would create too much artifact for MR examination * Pregnant or lactating patients. Women of childbearing potential and sexually active men must use an effective contraception method during rreatment and for three months after completing treatment. Patients of childbearing potential must have a negative serum or urine B-hCG pregnancy test at screening. * History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity) or macular degeneration. * QTc prolongation defined as a QTcF \> 500 ms * Known glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Symptomatic CIPN | Throughout study completion, an average of 6 months | The primary endpoint is symptomatic CIPN defined as increase in in FACT-GOG/Ntx-12 questionnaire score of greater than or equal to 3 points post-chemotherapy with hydroxychloroquine in combination with paclitaxel chemotherapy in patients with early-stage breast cancer or gynecologic malignancies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Predicting Symptomatic CIPN: FA and ADC values derived from DTI | Baseline | Baseline fractional anisotrophy (FA) and apparent diffusion coefficient (ADC) values derived from DTI will be used to predict symptomatic CIPN prior to starting and end of chemotherapy. |
| Predicting Symptomatic CIPN: change in FA and ADC | Baseline and 12 weeks | Change in mean FA and ADC prior to starting and end of chemotherapy will be calculated. The mean of the change in FA and ADC values with 95% confidence intervals will be estimated (post- minus pre- chemotherapy). The baseline values and the change of FA and ADC will be used to predict the development of symptomatic CIPN using logistic regression. |
| Predicting Symptomatic CIPN: baseline NF-L levels | Baseline | Baseline level of neurofilament light chain (NF-L) will be used to predict symptomatic CIPN. The baseline values will be used to predict development of symptomatic CIPN using logistic regression. |
| Predicting Symptomatic CIPN: Changes in NF-L levels | Baseline and 12 weeks | Changes in NF-L levels with chemotherapy used to predict development of symptomatic CIPN. NF-L measures will be summarized across time and analyzed using linear mixed effects model. |
Outcome results
None listed